Beijing, China

Fengzhi Zhang


Average Co-Inventor Count = 16.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):

Title: The Innovative Contributions of Inventor Fengzhi Zhang

Introduction

Fengzhi Zhang is a prominent inventor based in Beijing, China, who has made significant strides in the field of biomedicine. With 1 patent to his name, his work focuses on innovative solutions aimed at combating serious health conditions, particularly cancers.

Latest Patents

Fengzhi Zhang's notable patent involves antibodies or antigen-binding fragments that specifically bind to OX40. This patent presents a groundbreaking approach for the treatment of various diseases, including cancers. The antibodies comprise a heavy chain variable region that includes one or more complementarity-determining regions (CDRs) with defined amino acid sequences listed in SEQ ID NOs: 1-12. This innovation holds promise for advancing cancer therapies and improving patient outcomes.

Career Highlights

Zhang is currently employed at Bioduro (Beijing) Co., Ltd., where he collaborates with other skilled professionals in the field. His career reflects a commitment to translating scientific research into practical therapies aimed at improving healthcare solutions.

Collaborations

Throughout his career, Fengzhi Zhang has partnered with notable colleagues, including Jing Li and Guoqian Sun. These collaborations enhance the efficacy of their research and contribute to the development of cutting-edge treatments in their respective fields of expertise.

Conclusion

In conclusion, Fengzhi Zhang is a dedicated inventor whose innovative work in antibody technology has the potential to make a substantial impact on the treatment of cancers. His contributions highlight the importance of research and collaboration in the advancement of medical science and the potential for new therapies to emerge from innovations in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…